Lantern Pharma Inc.
For the period ended Sep 30, 2025. Filed Nov 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 12, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1A. Risk Factors
As a Smaller Reporting Company we are exempted from the requirements of Item 1A.
During the three months ended September 30, 2025, the Company issued 30,000 shares of common stock to a consultant in exchange for services having a fair value of approximately $134,000. The shares were issued pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Act”), set forth at Section 4(a)(2) of the Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.